FDA-cleared profile

ART-Plan+ (v.3.0.0)

Therapanacea SAS · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Clinical role
Radiotherapy image processing, contouring, planning, and release-dependent offline adaptation support
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: The software is an assistive radiation-planning system, not an autonomous treatment decision maker. Outputs require qualified review, correction, and approval before treatment use. FDA labeling excludes patients younger than 18 years for the later ART-Plan lineage reviewed in this batch; confirm the exact installed release labeling.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: DICOM radiation-planning images and objects. Release-dependent inputs include CT, MR, PET-CT, CBCT, 4D-CT, RT Structure Sets, prescriptions, and user-defined planning or adaptation parameters.
  • Who uses it?Intended users: Trained medical professionals involved in radiation therapy, including radiation oncologists, radiotherapists, medical physicists, dosimetrists, radiologists, and other qualified planning staff as specified by the release labeling.
  • What does the software produce?Output: Release-dependent outputs include reviewed contours and registrations, synthetic or pseudo-CT images, calculated dose information, replanning-assessment metrics, or an automatic plan for import into a treatment-planning system. Qualified users remain responsible for review and approval.
  • What is its most important limitation?Key limitation: The software is an assistive radiation-planning system, not an autonomous treatment decision maker. Outputs require qualified review, correction, and approval before treatment use. FDA labeling excludes patients younger than 18 years for the later ART-Plan lineage reviewed in this batch; confirm the exact installed release labeling.

Clinical takeaway. Clinical role: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Evidence takeaway. Evidence from the reviewed source record: FDA submissions document release-specific software verification, contouring validation, registration checks, and, where applicable, synthetic-CT, dose, planning, or adaptation testing. Independent multi-vendor studies support clinical usefulness but also show structure- and site-dependent editing needs; they do not validate every ART-Plan release or establish patient-outcome benefit.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy image processing, contouring, planning, and release-dependent offline adaptation support
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM radiation-planning images and objects. Release-dependent inputs include CT, MR, PET-CT, CBCT, 4D-CT, RT Structure Sets, prescriptions, and user-defined planning or adaptation parameters.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Release-dependent outputs include reviewed contours and registrations, synthetic or pseudo-CT images, calculated dose information, replanning-assessment metrics, or an automatic plan for import into a treatment-planning system. Qualified users remain responsible for review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained medical professionals involved in radiation therapy, including radiation oncologists, radiotherapists, medical physicists, dosimetrists, radiologists, and other qualified planning staff as specified by the release labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The software is an assistive radiation-planning system, not an autonomous treatment decision maker. Outputs require qualified review, correction, and approval before treatment use. FDA labeling excludes patients younger than 18 years for the later ART-Plan lineage reviewed in this batch; confirm the exact installed release labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
FDA submissions document release-specific software verification, contouring validation, registration checks, and, where applicable, synthetic-CT, dose, planning, or adaptation testing. Independent multi-vendor studies support clinical usefulness but also show structure- and site-dependent editing needs; they do not validate every ART-Plan release or establish patient-outcome benefit.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA submissions document release-specific software verification, contouring validation, registration checks, and, where applicable, synthetic-CT, dose, planning, or adaptation testing. Independent multi-vendor studies support clinical usefulness but also show structure- and site-dependent editing needs; they do not validate every ART-Plan release or establish patient-outcome benefit.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Exact FDA submission
  • Checked 2026-09-04

Sensitivity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Reported specificity
Not applicable
  • Not applicable
  • Exact FDA submission
  • Checked 2026-09-04

Specificity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Blinded review panel

20 radiation oncologists

  • EndpointReviewers in the multi-vendor contouring study
  • PopulationMulti-region radiotherapy contour review
  • Tested versionART-Plan product family; exact build not reported

K242822 FDA performance package for ART-Plan+ (v.3.0.0)

  • DesignManufacturer software verification and validation with release-specific contouring, registration, synthetic-CT, planning, dose, or adaptation tests as applicable
  • PopulationRelease-specific multi-region radiotherapy images, structures, registrations, and planning workflows described in the FDA summary
  • Scopeexact submission
  • Tested versionART-Plan+ v3.0.0
  • IndependenceSponsor or vendor study

K242822

Manufacturer evidence submitted for substantial equivalence. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Blinded multi-vendor clinical review of automatic OAR and lymph-node contouring

  • DesignBlinded comparative review of eight commercial contouring programs by 20 radiation oncologists
  • PopulationAdult and pediatric radiation-therapy contours across head and neck, thorax or breast, abdomen, and pelvis
  • Scopeproduct family
  • Tested versionART-Plan product family; exact tested build was not tied to every FDA submission in this batch
  • Samplen=20
  • IndependenceIndependent study

PMCID PMC11580215

The study reported that all evaluated systems required physician correction and should not be treated as exact-version validation.

K242822 FDA evidence package for ART-Plan+ (v.3.0.0)

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationMulti-region
  • Scopeexact submission
  • Tested versionART-Plan+ v3.0.0
  • IndependenceSponsor or vendor study

K242822

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242822 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM radiation-planning images and objects. Release-dependent inputs include CT, MR, PET-CT, CBCT, 4D-CT, RT Structure Sets, prescriptions, and user-defined planning or adaptation parameters.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0)

  2. Routing

    Source context, not route validation: DICOM 3.0 import, export, and network exchange with imaging systems and treatment-planning systems; exact supported objects and automation depend on the cleared release and local configuration.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0) · ART-Plan AI application suite for radiotherapy

  3. AI processing

    Source context, not route validation: Software platform used in radiation-therapy hospitals and clinics. FDA summaries describe account-based projects, browser-accessible functions in later releases, DICOM network exchange, and batch-mode operations; hosting, tenancy, interfaces, and compute sizing require site-specific confirmation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0) · ART-Plan AI application suite for radiotherapy

  4. Returned objects

    Source context, not route validation: Release-dependent outputs include reviewed contours and registrations, synthetic or pseudo-CT images, calculated dose information, replanning-assessment metrics, or an automatic plan for import into a treatment-planning system. Qualified users remain responsible for review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0)

  5. Viewer/worklist/report

    Unresolved route: Release-dependent outputs include reviewed contours and registrations, synthetic or pseudo-CT images, calculated dose information, replanning-assessment metrics, or an automatic plan for import into a treatment-planning system. Qualified users remain responsible for review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software platform used in radiation-therapy hospitals and clinics. FDA summaries describe account-based projects, browser-accessible functions in later releases, DICOM network exchange, and batch-mode operations; hosting, tenancy, interfaces, and compute sizing require site-specific confirmation.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
DICOM 3.0 import, export, and network exchange with imaging systems and treatment-planning systems; exact supported objects and automation depend on the cleared release and local configuration.
  • Exact FDA submission
  • Checked 2026-09-04
Security
TheraPanacea's security page publishes a coordinated vulnerability disclosure policy: reports to security@therapanacea.com with a published PGP key, acknowledgement within 3 business days, triage within 10 business days, updates at least every 30 days, coordinated publication 90 days after acknowledgement by default, fixes on the timelines of its vulnerability management policy, and direct notification of affected customers with affected versions, fixes and mitigations. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. The page is on therapanacea.com and describes TheraPanacea's radiotherapy planning and delivery software; the FDA applicant name variants (TheraPanacea, Therapanacea SAS) match. Company-wide statement; exact-release scope is not established.

Training
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K242822 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

DICOM 3.0 import, export, and network exchange with imaging systems and treatment-planning systems; exact supported objects and automation depend on the cleared release and local configuration.

exact submission · checked 2026-09-04

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-04

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-04

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Deployment boundary

The exact installed deployment, hosting, service, security, and operational boundary remains unverified and requires site-specific confirmation.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242822
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
13Source classes checked
20Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 20 PubMed titles and one trial record. None identifies ART-Plan+ v3.0.0 or K242822 and establishes the tested release; all 21 candidates are quarantined as adaptive-radiotherapy topic matches. The current discovery snapshot contains 20 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, fda decision material, peer reviewed literature, clinical trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

13 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K242822: ART-Plan+ (v.3.0.0)

    U.S. Food and Drug Administration - Published 2025-02-25 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  8. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning

    National Institute for Health and Care Excellence - Published 2023-09-27 - Accessed 2026-09-02

    Scope: limitations, training, pricing, evidenceSummary, economics, monitoring, implementationCapabilities

  9. ART-Plan AI application suite for radiotherapy

    TheraPanacea SAS - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, currentCommercialContext, implementationCapabilities

  10. AdaptBox offline adaptive radiotherapy workflow

    TheraPanacea SAS - Accessed 2026-09-03

    Scope: workflowRole, integration, deployment, currentCommercialContext, implementationCapabilities

  11. Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas

    BMC Cancer - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring, implementationCapabilities

  12. Guidance on selecting and evaluating AI auto-segmentation systems in clinical radiotherapy

    Journal of Applied Clinical Medical Physics - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, economics, monitoring, implementationCapabilities

  13. TheraPanacea: Security (coordinated vulnerability disclosure policy)

    TheraPanacea - Accessed 2026-10-26

    Scope: security

Research history

  1. K242822 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K240398

RayStation 2023B, RayPlan 2023B, RayStation 2024A, RayPlan 2024A, RayStation 2024A SP3, RayPlan 2024A SP3

RaySearch Laboratories AB (PUBL)

Authorized purpose: RayStation and RayPlan releases covered by K240398 are configurable radiotherapy and medical-oncology software that proposes or supports treatment plans from user inputs, with authorized users required to review and approve plans before treatment.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-04
FDA-cleared K242994

OncoStudio (OS-01)

OncoSoft. Co., Ltd.

Authorized purpose: OncoStudio OS-01 creates initial deep-learning organs-at-risk contours from CT images of the head and neck, thorax, abdomen, and pelvis for radiation-oncology review, editing, and DICOM RT export.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history